KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Deferred Revenue (2016 - 2022)

Historic Current Deferred Revenue for Emergent BioSolutions (EBS) over the last 14 years, with Q1 2022 value amounting to $15.9 million.

  • Emergent BioSolutions' Current Deferred Revenue fell 8590.43% to $15.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $15.9 million, marking a year-over-year decrease of 8590.43%. This contributed to the annual value of $16.4 million for FY2021, which is 8361.64% down from last year.
  • According to the latest figures from Q1 2022, Emergent BioSolutions' Current Deferred Revenue is $15.9 million, which was down 8590.43% from $16.4 million recorded in Q4 2021.
  • Emergent BioSolutions' 5-year Current Deferred Revenue high stood at $118.0 million for Q2 2020, and its period low was $9.8 million during Q2 2018.
  • Moreover, its 5-year median value for Current Deferred Revenue was $82.1 million (2021), whereas its average is $71.8 million.
  • In the last 5 years, Emergent BioSolutions' Current Deferred Revenue soared by 81794.87% in 2019 and then tumbled by 8590.43% in 2022.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Current Deferred Revenue stood at $73.1 million in 2018, then increased by 21.61% to $88.9 million in 2019, then increased by 12.6% to $100.1 million in 2020, then tumbled by 83.62% to $16.4 million in 2021, then dropped by 3.05% to $15.9 million in 2022.
  • Its Current Deferred Revenue was $15.9 million in Q1 2022, compared to $16.4 million in Q4 2021 and $82.1 million in Q3 2021.